[1] Hirsch E C, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?[J]. Lancet Neurol, 2009, 8(4):382-397.[2] Tansey M G, Goldberg M S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention[J]. Neurobiol Dis, 2010, 37(3):510-518.[3] McGeer P L, Itagaki S, Boyes B E, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains[J]. Neurology, 1988, 38(8):1285-1291.[4] Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease[J]. Ann Neurol, 2005, 57(2):168-175.[5] Long-Smith C M, Sullivan A M, Nolan Y M. The influence of microglia on the pathogenesis of Parkinson's disease[J]. Prog Neurobiol, 2009, 89(3):277-287.[6] Marinova-Mutafchieva L, Sadeghian M, Broom L, et al. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease[J]. J Neurochem, 2009, 110(3):966-975.[7] Arimoto T, Choi D Y, Lu X, et al. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra[J]. Neurobiol Aging, 2007, 28(6):894-906.[8] Feng Z H, Wang T G, Li D D, et al. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl 1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra[J]. Neurosci Lett, 2002, 329(3):354-358.[9] Vijitruth R, Liu M, Choi D Y, et al. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease[J]. J Neuroinflammation, 2006, 3:6.[10] Liberatore G T, Jackson-Lewis V, Vukosavic S, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease[J]. Nat Med, 1999, 5(12):1403-1409.[11] Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells[J]. Lancet, 2004, 363(9419):1439-1441.[12] Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versushost disease: a phase Ⅱ study[J]. Lancet, 2008, 371(9624):1579——1586.[13] Di Nicola M, Carlo-stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli[J]. Blood, 2002, 99(10):3838-3843.[14] Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions[J]. Blood, 2006, 107(1):367-372.[15] Spaggiari G M, Capobianco A, Abdelrazik H, et al. Mesenchymal stem cells inhibit natural killer cell proliferation, cytotoxicity and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2[J]. Blood, 2008, 111(3):1327-1333.[16] 寿培舜, 黄寅, 苏娟娟, 等.间充质干细胞免疫抑制机制及在疾病中的应用[J].细胞生物学杂志, 2009, 31(1):15-20.[17] 王晓辉, 罗芸, 贾庆华, 等.Notch1对人脐带间充质干细胞增殖、黏附及迁移影响的体外研究[J].解放军医药杂志, 2013, 25(10):16-21.[18] Yoo K H, Jang I K, Lee M W, et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues[J]. Cell Immunol, 2009, 259(2):150-156.[19] Hughes A J, Daniel S E, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases[J].J Neurol Neurosurg Psychiatry, 1992, 55(3):181-184.[20] Asanuma M, Miyazaki I. Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?[J]. Exp Neurol, 2007, 206(2):172-178.[21] Samii A, Etminan M, Wiens M O, et al. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies[J]. Drugs Aging, 2009, 26(9):769-779.[22] Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide[J]. Cell Stem Cell, 2008, 2(2):141-150. |